Health Rounds newsletter excerpt has been corrected to indicate in the headline and the first item of the story that Sanofi ...

An experimental drug being developed by Sanofi significantly curbed progression of aortic valve stenosis, a common heart ...

Ataciguat, a new drug being studied for aortic valve stenosis, shows promise in slowing disease progression and reducing the ...

Roger Black required surgery after blaming his weariness on simply getting older and the Olympic silver medalist was given a ...

More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the American Heart Association ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally. Researchers are exploring the use of a new drug called ataciguat to manage ...

An experimental drug, ataciguat, initially created by Sanofi and further developed by the Mayo Clinic, has significantly ...

More than 60,000 people die from heart valve disease (HVD) in the U.S. each year, according to the American Heart Association ...

Aortic valve stenosis (AVS) is a significant health concern affecting over 1.5 million Americans and millions more globally.

Heart Valve Disease Awareness Day, observed annually on February 22, is dedicated to educating the public about the risks, ...

Sanofi's experimental drug ataciguat has shown promise in reducing the progression of aortic valve stenosis in clinical trials, potentially delaying the need for surgical valve replacement. With ...

As part of National Heart Valve Disease Awareness Day area cardiologists ... and four doors (valves)" the aortic, mitral, pulmonary, and tricuspid valves. Each has their importance to the proper ...